Startseite Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study

  • Lorenz Kuessel , Heinrich Husslein EMAIL logo , Eliana Montanari , Michael Kundi , Gottfried Himmler , Julia Binder , Judith Schiefer und Harald Zeisler
Veröffentlicht/Copyright: 17. Oktober 2019
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 58 Heft 1

Abstract

Background

We investigated the dynamics and the predictive value of soluble syndecan-1 (Sdc-1), a biomarker of endothelial dysfunction, in uneventful pregnancies and pregnancies complicated by preeclampsia (PE).

Methods

Serum levels of Sdc-1 were measured at sequential time points during and after uneventful pregnancies (control, n = 95) and pregnancies developing PE (PE_long, n = 12). Levels were further measured in women with symptomatic PE (PE_state, n = 46) at a single time point.

Results

Sdc-1 levels increased consistently throughout pregnancy. In the PE_long group Sdc-1 levels were lower at all visits throughout pregnancy, and reached significance in weeks 18–22 (p = 0.019), 23–27 (p = 0.009), 28–32 (p = 0.006) and 33–36 (p = 0.008). After delivery, Sdc-1 levels dropped sharply in all pregnancies but were significantly elevated in the PE_long group. The predictive power of Sdc-1 was evaluated analyzing receiver operating characteristic (ROC) curves. A significant power was reached at weeks 14–17 (area under the curve [AUC] 0.65, p = 0.025), 23–27 (AUC 0.73, p = 0.004) and 33–36 (AUC 0.75, p = 0.013).

Conclusions

In summary, Sdc-1 levels were lower in women developing PE compared to uneventful pregnancies and Sdc-1 might be useful to predict PE. After delivery, Sdc-1 levels remained higher in women with PE. Additional studies investigating the link between glycocalyx degradation, Sdc-1 levels and placental and endothelial dysfunction in pregnancies affected by PE are warranted.

Keywords: biomarker; endothelial dysfunction; glycocalyx degradation; preeclampsia; soluble syndecan-1
Corresponding author: Heinrich Husslein, MD, PLLM, Associate Professor, Department of Gynecology and Obstetrics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria, Phone: +43 1 40400 28 810

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–7.10.1053/j.semperi.2009.02.010Suche in Google Scholar

2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review.Lancet 2006;367:1066–74.10.1016/S0140-6736(06)68397-9Suche in Google Scholar

3. Hahn S, Huppertz B, Holzgreve W. Fetal cells and cell free fetal nucleic acids in maternal blood: new tools to study abnormal placentation? Placenta 2005;26:515–26.10.1016/j.placenta.2004.10.017Suche in Google Scholar

4. Myatt L. Role of placenta in preeclampsia. Endocrine 2002;19:103–11.10.1385/ENDO:19:1:103Suche in Google Scholar

5. Prefumo F, Sebire NJ, Thilaganathan B. Decreased endovascular trophoblast invasion in first trimester pregnancies with high-resistance uterine artery Doppler indices. Hum Reprod 2004;19:206–9.10.1093/humrep/deh037Suche in Google Scholar PubMed

6. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011;31:33–46.10.1016/j.semnephrol.2010.10.004Suche in Google Scholar PubMed PubMed Central

7. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol 2010;63:534–43.10.1111/j.1600-0897.2010.00831.xSuche in Google Scholar PubMed

8. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30(Suppl A):S32–7.10.1016/j.placenta.2008.11.009Suche in Google Scholar PubMed PubMed Central

9. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016;374:13–22.10.1056/NEJMoa1414838Suche in Google Scholar PubMed

10. Tarbell JM, Cancel LM. The glycocalyx and its significance in human medicine. J Intern Med 2016;280:97–113.10.1111/joim.12465Suche in Google Scholar PubMed

11. Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010;53:2646–55.10.1007/s00125-010-1910-xSuche in Google Scholar PubMed PubMed Central

12. Lemkes BA, Nieuwdorp M, Hoekstra JB, Holleman F. The glycocalyx and cardiovascular disease in diabetes: should we judge the endothelium by its cover? Diabetes Technol Ther 2012;14 Suppl 1:S3–10.10.1089/dia.2012.0011Suche in Google Scholar PubMed

13. Nussbaum C, Cavalcanti Fernandes Heringa A, Mormanova Z, Puchwein-Schwepcke AF, Bechtold-Dalla Pozza S, Genzel-Boroviczény O. Early microvascular changes with loss of the glycocalyx in children with type 1 diabetes. J Pediatr 2014;164:584–9.e1.10.1016/j.jpeds.2013.11.016Suche in Google Scholar PubMed

14. Steppan J, Hofer S, Funke B, Brenner T, Henrich M, Martin E, et al. Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalix. J Surg Res 2011;165:136–41.10.1016/j.jss.2009.04.034Suche in Google Scholar PubMed

15. Annecke T, Fischer J, Hartmann H, Tschoep J, Rehm M, Conzen P, et al. Shedding of the coronary endothelial glycocalyx: effects of hypoxia/reoxygenation vs. ischaemia/reperfusion. Br J Anaesth 2011;107:679–86.10.1093/bja/aer269Suche in Google Scholar PubMed

16. Weissgerber TL, Garcia-Valencia O, Milic NM, Codsi E, Cubro H, Nath MC, et al. Early onset preeclampsia is associated with glycocalyx degradation and reduced microvascular perfusion. J Am Heart Assoc 2019;8:e010647.10.1161/JAHA.118.010647Suche in Google Scholar PubMed PubMed Central

17. Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol 2012;31:3–16.10.1016/j.matbio.2011.10.001Suche in Google Scholar PubMed PubMed Central

18. Stepp MA, Pal-Ghosh S, Tadvalkar G, Pajoohesh-Ganji A. Syndecan-1 and its expanding list of contacts. Adv Wound Care (New Rochelle) 2015;4:235–49.10.1089/wound.2014.0555Suche in Google Scholar PubMed PubMed Central

19. Luo L, Feng S, Wu Y, Su Y, Jing F, Yi Q. Serum levels of syndecan-1 in patients with Kawasaki disease. Pediatr Infect Dis J 2019;38:89–94.10.1097/INF.0000000000002047Suche in Google Scholar PubMed PubMed Central

20. Gandley RE, Althouse A, Jeyabalan A, Bregand-White JM, McGonigal S, Myerski AC, et al. Low soluble syndecan-1 precedes preeclampsia. PLoS One 2016;11:e0157608.10.1371/journal.pone.0157608Suche in Google Scholar PubMed PubMed Central

21. Hofmann-Kiefer KF, Knabl J, Martinoff N, Schiessl B, Conzen P, Rehm M, et al. Increased serum concentrations of circulating glycocalyx components in HELLP syndrome compared to healthy pregnancy: an observational study. Reprod Sci 2013;20:318–25.10.1177/1933719112453508Suche in Google Scholar

22. Kuessel L, Zeisler H, Ristl R, Binder J, Pateisky P, Schmid M, et al. The usefulness of CYFRA 21-1 to diagnose and predict preeclampsia: a nested case-control study. BMC Pregnancy Childb 2016;16:339.10.1186/s12884-016-1132-4Suche in Google Scholar

23. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143–8.10.1081/PRG-120021060Suche in Google Scholar

24. Practice ACoO. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77:67–75.Suche in Google Scholar

25. Redman CW, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 2015;213:S9.e1, S9–11.10.1016/j.ajog.2015.08.003Suche in Google Scholar

26. Chui A, Murthi P, Brennecke SP, Ignjatovic V, Monagle PT, Said JM. The expression of placental proteoglycans in pre-eclampsia. Gynecol Obstet Invest 2012;73:277–84.10.1159/000333262Suche in Google Scholar

27. Crescimanno C, Marzioni D, Paradinas FJ, Schrurs B, Mühlhauser J, Todros T, et al. Expression pattern alterations of syndecans and glypican-1 in normal and pathological trophoblast. J Pathol 1999;189:600–8.10.1002/(SICI)1096-9896(199912)189:4<600::AID-PATH440>3.0.CO;2-QSuche in Google Scholar

28. Jokimaa V, Inki P, Kujari H, Hirvonen O, Ekholm E, Anttila L. Expression of syndecan-1 in human placenta and decidua. Placenta 1998;19:157–63.10.1016/S0143-4004(98)90004-2Suche in Google Scholar

29. Jokimaa VI, Kujari HP, Ekholm EM, Inki PL, Anttila L. Placental expression of syndecan 1 is diminished in preeclampsia. Am J Obstet Gynecol 2000;183:1495–8.10.1067/mob.2000.107320Suche in Google Scholar

30. Mulivor AW, Lipowsky HH. Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 2004;286:H1672–80.10.1152/ajpheart.00832.2003Suche in Google Scholar

31. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007;116:1896–906.10.1161/CIRCULATIONAHA.106.684852Suche in Google Scholar

32. Mundt F, Heidari-Hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K. Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int 2014;2014:419853.10.1155/2014/419853Suche in Google Scholar

33. Yablecovitch D, Stein A, Shabat-Simon M, Naftali T, Gabay G, Laish I, et al. Soluble Syndecan-1 levels are elevated in patients with inflammatory bowel disease. Dig Dis Sci 2015;60:2419–26.10.1007/s10620-015-3589-9Suche in Google Scholar

34. Szabo S, Xu Y, Romero R, Fule T, Karaszi K, Bhatti G, et al. Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. Virchows Arch 2013;463:445–58.10.1007/s00428-013-1426-0Suche in Google Scholar

35. Weissgerber TL, Milic NM, Milin-Lazovic JS, Garovic VD. Impaired flow-mediated dilation before, during, and after preeclampsia: a systematic review and meta-analysis. Hypertension 2016;67:415–23.10.1161/HYPERTENSIONAHA.115.06554Suche in Google Scholar

36. Yinon Y, Kingdom JC, Odutayo A, Moineddin R, Drewlo S, Lai V, et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010;122:1846–53.10.1161/CIRCULATIONAHA.110.948455Suche in Google Scholar

37. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200–4.10.1016/0002-9378(89)90665-0Suche in Google Scholar

38. Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens 2015;24: 131–8.10.1097/MNH.0000000000000105Suche in Google Scholar PubMed

39. Wenger NK. Recognizing pregnancy-associated cardiovascular risk factors. Am J Cardiol 2014;113:406–9.10.1016/j.amjcard.2013.08.054Suche in Google Scholar PubMed

Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0686).

Received: 2019-07-06
Accepted: 2019-09-23
Published Online: 2019-10-17
Published in Print: 2019-12-18

©2020 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Reflex TSH strategy: the good, the bad and the ugly
  4. Review
  5. Shortcomings in the evaluation of biomarkers in ovarian cancer: a systematic review
  6. Mini Review
  7. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates
  8. Opinion Paper
  9. Gut microbiotas and immune checkpoint inhibitor therapy response: a causal or coincidental relationship?
  10. EFLM Paper
  11. Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of 20 haematological parameters
  12. General Clinical Chemistry and Laboratory Medicine
  13. Pre-, post- or no acidification of urine samples for calcium analysis: does it matter?
  14. Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis
  15. Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study
  16. Multi-site performance evaluation and Sigma metrics of 20 assays on the Atellica chemistry and immunoassay analyzers
  17. Plasma creatinine medians from patients partitioned by gender and age used as a tool for assessment of analytical stability at different concentrations
  18. Two-center comparison of 10 fully-automated commercial procalcitonin (PCT) immunoassays
  19. Method comparison of four clinically available assays for serum free light chain analysis
  20. Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone
  21. Repeatability and reproducibility of lipoprotein particle profile measurements in plasma samples by ultracentrifugation
  22. Reference Values and Biological Variations
  23. A study on reference interval transference via linear regression
  24. Cancer Diagnostics
  25. Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer
  26. Cardiovascular Diseases
  27. Analytical validation of a highly sensitive point-of-care system for cardiac troponin I determination
  28. Acknowledgment
  29. Letters to the Editor
  30. Are icteric and lipemic indices reliable to screen for hyperbilirubinemia and hypertriglyceridemia?
  31. Anti-streptavidin antibodies as a cause of false-positive results of streptavidin-based autoantibody assays
  32. Assessment of complement interference in anti-Müllerian hormone immunoassays
  33. Validating thyroid-stimulating hormone (TSH) reflexive testing cutpoints in a tertiary care institution
  34. Results of the second external quality assessment for human papillomavirus genotyping in Shanghai, China
  35. Development of suitable external quality control material for G6PD deficiency screening with the fluorescent spot test
  36. Non-linearity in commercially available lipase assays: still gaps to close
  37. JAK2, 46/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential
  38. Congress Abstracts
  39. 11th National Scientifc Congress SPML
https://doi.org/10.1515/cclm-2019-0686
Schlagwörter für diesen Artikel
biomarker; endothelial dysfunction; glycocalyx degradation; preeclampsia; soluble syndecan-1

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Reflex TSH strategy: the good, the bad and the ugly
  4. Review
  5. Shortcomings in the evaluation of biomarkers in ovarian cancer: a systematic review
  6. Mini Review
  7. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates
  8. Opinion Paper
  9. Gut microbiotas and immune checkpoint inhibitor therapy response: a causal or coincidental relationship?
  10. EFLM Paper
  11. Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of 20 haematological parameters
  12. General Clinical Chemistry and Laboratory Medicine
  13. Pre-, post- or no acidification of urine samples for calcium analysis: does it matter?
  14. Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis
  15. Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study
  16. Multi-site performance evaluation and Sigma metrics of 20 assays on the Atellica chemistry and immunoassay analyzers
  17. Plasma creatinine medians from patients partitioned by gender and age used as a tool for assessment of analytical stability at different concentrations
  18. Two-center comparison of 10 fully-automated commercial procalcitonin (PCT) immunoassays
  19. Method comparison of four clinically available assays for serum free light chain analysis
  20. Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone
  21. Repeatability and reproducibility of lipoprotein particle profile measurements in plasma samples by ultracentrifugation
  22. Reference Values and Biological Variations
  23. A study on reference interval transference via linear regression
  24. Cancer Diagnostics
  25. Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer
  26. Cardiovascular Diseases
  27. Analytical validation of a highly sensitive point-of-care system for cardiac troponin I determination
  28. Acknowledgment
  29. Letters to the Editor
  30. Are icteric and lipemic indices reliable to screen for hyperbilirubinemia and hypertriglyceridemia?
  31. Anti-streptavidin antibodies as a cause of false-positive results of streptavidin-based autoantibody assays
  32. Assessment of complement interference in anti-Müllerian hormone immunoassays
  33. Validating thyroid-stimulating hormone (TSH) reflexive testing cutpoints in a tertiary care institution
  34. Results of the second external quality assessment for human papillomavirus genotyping in Shanghai, China
  35. Development of suitable external quality control material for G6PD deficiency screening with the fluorescent spot test
  36. Non-linearity in commercially available lipase assays: still gaps to close
  37. JAK2, 46/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential
  38. Congress Abstracts
  39. 11th National Scientifc Congress SPML
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 21.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2019-0686/html
Button zum nach oben scrollen